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SI Detailed (Extended) Legend to Fig. 1
Fig. 1 shows the mammalian N-end rule pathway and the Ate1
arginyltransferase (R-transferase). The main determinant of an
N-degron is a destabilizing N-terminal residue of a protein. N-ter-
minal residues are indicated by single-letter abbreviations for amino
acids. A yellow oval denotes the rest of a protein substrate. Rec-
ognition components of the N-end rule pathway are called N-rec-
ognins. In eukaryotes, the N-end rule pathway consists of two
branches, the Arg/N-end rule pathway (Fig. 1A) and the Ac/N-end
rule pathway (Fig. 1B) (refs. 1–60 and references therein).
(Fig. 1A) The Arg/N-end rule pathway targets specific un-
acetylated N-terminal residues. In the yeast Saccharomyces
cerevisiae, the Arg/N-end rule pathway is mediated by the Ubr1 N-
recognin, a 225-kDa RING-type E3 Ub ligase and a part of the
targeting apparatus comprising a complex of the Ubr1-Rad6 and
Ufd4-Ubc4/5 holoenzymes (1, 5, 10). In multicellular eukaryotes,
several functionally overlapping E3 Ub ligases (Ubr1, Ubr2, Ubr4,
and Ubr5) function as N-recognins of this pathway. An N-recog-
nin binds to the “primary” destabilizing N-terminal residues Arg,
Lys, His, Leu, Phe, Tyr, Trp, and Ile. In contrast, the N-terminal
Asn, Gln, Asp, and Glu residues (as well as Cys, under some
metabolic conditions) are destabilizing because of their pre-
liminary enzymatic modifications. These modifications include the
Nt-deamidation of N-terminal Asn and Gln by the Ntan1 and
Ntaq1 Nt-amidases, respectively, and the Nt-arginylation of
N-terminal Asp and Glu by the Ate1 R-transferase, which can also
Nt-arginylate oxidized Cys, either Cys-sulfinate or Cys-sulfonate.
These derivatives can form in animal and plant cells through ox-
idation of N-terminal Cys by nitric oxide (NO) and oxygen, and
also by N-terminal Cys-oxidases (15, 23, 30, 32, 61–64). In addition
to its type 1 and type 2 binding sites that recognize, respectively,
the basic and bulky hydrophobic unacetylated N-terminal residues,
an N-recognin such as Ubr1 contains other substrate-binding sites
as well. These sites recognize substrates that are targeted through
their internal (non–N-terminal) degrons, as indicated in the dia-
gram (1). Hemin (Fe3+-heme) binds to the Ate1 R-transferase,
inhibits its Nt-arginylation activity and accelerates its in vivo
degradation. Hemin also binds to Ubr1 and alters its functional
properties, in ways that remain to be understood (14). As shown in
the diagram, the unacetylated Met of the N-terminal Met-hydro-
phobic residue (MΦ) motif was found to be recognized by both
yeast and mammalian Ubr1, thereby greatly expanding the sub-
strate range of the Arg/N-end rule pathway (60).
(Fig. 1B) The Ac/N-end rule pathway. This diagram illustrates
the mammalian Ac/N-end rule pathway through extrapolation from
its S. cerevisiae version. Red arrow on the left indicates the removal
of N-terminal Met by Met-aminopeptidases (MetAPs). N-terminal
Met is retained if a residue at position 2 is nonpermissive (too
large) for MetAPs. If the retained N-terminal Met or N-terminal
Ala, Ser, Thr are followed by acetylation-permissive residues, the
above N-terminal residues are Nα-terminally acetylated (Nt-acety-
lated) by ribosome-associated Nt-acetylases (65–67). Nt-terminal
Val and Cys are Nt-acetylated relatively rarely, whereas N-terminal
Pro and Gly are almost never Nt-acetylated. (N-terminal Gly is
often N-myristoylated.) N-degrons and N-recognins of the Ac/N-
end rule pathway are called Ac/N-degrons and Ac/N-recognins,
respectively (1). The term “secondary” refers to Nt-acetylation of
a destabilizing N-terminal residue before a protein can be recog-
nized by a cognate Ac/N-recognin. Natural Ac/N-degrons are
regulated by their reversible steric shielding in protein com-
plexes (60, 68).
(Fig. 1C) The bidirectional DfaPAte1 promoter upstream of
exon 1B of mouse Ate1 (1, 50, 69).
(Fig. 1D) Four major mouse Ate1 R-transferase isoforms and
their designations (1, 50).
SI Experimental Procedures
Y2H Assays. Y2H assays were carried out using the BD Match-
maker kit (BD Biosciences). Briefly, S. cerevisiae AH109 (MATa
trp1-901 leu2-3, 112 ura3-52 his3-200 Gal4Δ gal80, LYS2::
GAL1UAS-GAL1TATA-HIS3 GAL2UAS-GAL2TATA-ADE2 URA3::
MEL1UAS-MEL1TATA-lacZ, MEL1) was transformed with
pCB132, which expressed the Gal4DBD-ATE11B7A fusion protein
(Table S1). The resulting strain (AH109-Ate11B7A) was mated
with S. cerevisiae Y187 (MATα ura3-52 his3-200 ade2-101 trp1-90
leu2-3, 112, gal4Δ gal80Δ met− URA3::GAL1UAS-GAL1TATA-lacZ
MEL1) that had been pretransformed with a mouse testis cDNA
pACT library (Clontech). The resulting diploids were incubated
on plates with synthetic-complete (SC) medium containing 5 mM
3-aminotriazole (Sigma) and lacking His, Trp, and Leu. [Trp+
Leu+ His+ ] isolates (∼1.5 × 106 cells) were further assayed for
their growth on His-lacking, Ade-lacking media, and also for
their β-galactosidase (βgal) activity. Colonies that were both
[Trp+ Leu+ His+ Ade+] and exhibited βgal activity were then
grown in Leu-lacking, Trp-containing media to facilitate the
loss of pCB132. The pA6 plasmid was recovered from one
strongly positive colony (called “A6”). The sequencing of
pA6 insert identified full-length mouse Liat1 as a potential
Ate11B7A-binding protein.
Vector-swapping experiments to verify detected interactions
were then carried out by excising (using BamHI and SalI) the
Ate11B7A ORF from pCB132, and by excising (using NdeI and
XhoI) the Liat1 ORF from the pA6 plasmid. The Ate11B7A ORF
was then subcloned into pACT2 (Table S1) to yield pCB135, the
Liat1 ORF was subcloned into pAS2 to yield pCB239, and Y2H
assays were repeated, as described above.
Additional two-hybrid assays with Liat1 and its derivatives were
carried out by cotransformation of S. cerevisiae AH109 with
plasmids expressing Gal4DBD-Liat1 (pCB239) and either Gal4AD-
Ate11B7B (pCB165) or Gal4AD-Ate11A7A (pCB167), as well as
with pCB432 (expressing Gal4AD-Liat1) and either pCB164 (ex-
pressing Gal4DBD-Ate11B7B) or pCB166 (expressing Gal4DBD-
Ate11A7A). The mapping of Ate1–Liat1 interactions was carried
out by cotransformation of S. cerevisiae AH109 with pCB132
(expressing Gal4DBD-ATE11B7A) and plasmids that expressed
various (indicated in Fig. 3B) segments of mouse Liat1 fused to
the Gal4AD (the plasmids pCB432, pCB433, pCB434, pCB435,
pCB436, pCB437, pCB438, pCB439, pCER-020, pCER-21,
pCER-022) (Table S1). Positive two-hybrid controls used plasmids
expressing Gal4DBD-WASP (pCB142) and Gal4AD-Cdc42 (pCB141)
(Table S1).
A separate two-hybrid screen for Liat1-binding proteins was
carried out by mating S. cerevisiae AH109 [pretransformed with
pCB239 (Table S1)] to S. cerevisiae Y187 [pretransformed with
a mouse brain cDNA library (Clontech)], and by carrying out
two-hybrid assays as described above.
In Vitro Arginylation Assay. The N-terminal arginylation (Nt-
arginylation) assay was performed as described previously (50),
with slight modifications. Briefly, the untagged mouse Liat1,
Ate11A7A, Ate11A7B, Ate11B7A, and Ate11B7B were expressed as
described below, using the Ub fusion/deubiquitylase-based pH10UE
expression system (70). The Nt-arginylation reporter X-DHFRbt
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(X = Asp, Cys or Arg-Cys) was prepared by expressing His10-Ub-X-
DHFRbt (X =Asp, Cys, or Arg-Cys) using the pH10UE expression/
purification system and precleaved with the Usp2cc deubiquitylase
(70) as described above, except that the cleaved reporter protein was
not purified further before Nt-arginylation assays. For Nt-arginyla-
tion, purified Liat1 and specific Ate1 isoforms were mixed (as in-
dicated in the main text and the legend to Fig. S5) together with
5.8 μM 14C-Arg (Perkin-Elmer NEC267E050UC; 346 mCi/mmol),
Escherichia coli tRNA (0.6 mg/mL), E. coli aminoacyl-tRNA syn-
thetases (800 U/mL) (Sigma) in 5 mM ATP, 0.15 M KCl, 10 mM
MgCl2, 1 mMDTT, 50 mMTris·HCl (pH 8.0), and preincubated for
15 min at 37 °C. A sample of (deubiquitylase-cleaved) reporter
(10 μg) was then added, followed by incubation for 60 min at 37 °C.
Reactions were stopped by the addition of a concentrated SDS-
sample buffer to the final concentration of 1× and heating at 95 °C
for 3 min, followed by SDS/4–12% PAGE, electroblotting to Im-
mobilon-P membrane (Millipore), and 14C-autoradiography, with
quantification using PhosphorImager.
Tissue Extracts and Immunoblotting. Animal care and related pro-
cedures were carried out according to relevant NIH guidelines, and
were approved (Protocol #1328) by the Institutional Animal Care
and Use Committee, the Office of Laboratory Animal Research at
the California Institute of Technology. Specific mouse tissues were
harvested and lysed in 0.05% Nonidet P-40, 10% (vol/vol) glycerol,
0.15 M NaCl, 2 mM EDTA, 1 mM DTT (DTT), 1 mM phe-
nylmethylsulfonyl fluoride, 50 mM Hepes (pH 7.5) containing
freshly dissolved “Complete EDTA-Free Protease Inhibitors”
(Roche), using the MP FastPrep-24 instrument and Lysing Matrix
D (MP Biomedicals), with two or three runs at 6.5 m/s for 25 s
each, and with 5-min incubations on ice between the runs. The
lysates were centrifuged at 10,000 × g for 20 min at 4 °C. The
supernatants were fractionated by SDS/12.5% PAGE, transferred
to Immobilon-P PVDF membranes, and analyzed by immuno-
blotting with a rabbit polyclonal anti-C17orf97 antibody (Sigma;
HPA023583). Immunoblots were visualized using the Odyssey
(Li-Cor) system, with donkey anti-rabbit IgG conjugated to an
infrared dye (Li-Cor; #926–32213) as secondary antibody.
Construction and Expression of Recombinant Proteins in BL21 (DE3)
E. coli.Untagged mouse Liat1 and Ate1 cDNAs were amplified by
PCR using primers flanked by the SacII and HindIII sites. The
resulting DNA fragments were subcloned into SacII/HindIII-cut
pH10UE, yielding the plasmids pCER-006 (Liat1), pCB407
(Ate11B7A), pCB408 (Ate11B7B), pCB409 (Ate11A7A), and pCB410
(Ate11A7B), which expressed His10-Ub-tagged fusions of the Ub
fusion technique (70) (Table S1). A cDNA encoding the N-termi-
nally triply ha-tagged mouse Liat1 (3haLiat1) was constructed using
a multistep PCR protocol. In particular, Liat1 ORF was amplified
from the plasmid pA6 (Table S1). The plasmid pCB403, expressing
the N-terminally triple ha-tagged mouse Liat1 (3haLiat1), was con-
structed by subcloning the above 3haLiat1-encoding DNA fragment
into SacII/HindIII-cut pH10UE, yielding pCB403 (Table S1).
Either 2-L cultures (for Ate1 production) or 4-L cultures (for
Liat1 production) of E. coli BL21(DE3) expressing one of the
above-cited plasmids were grown at 37 °C to an A600 of ∼0.6 in
Luria Broth (LB) containing ampicillin (50 μg/mL). The cultures
were placed on ice for 45 min, followed by the addition of iso-
propyl-β-D-thiogalactoside to the final concentration of 0.25 mM
and incubation, with shaking, for 6 h at room temperature. Cells
were harvested by centrifugation at 2,000 × g for 10 min at 4 °C.
Cell pellets were resuspended in either 15 mL or 30 mL of PBS
containing 30% (vol/vol) glycerol, 0.3 M NaCl, 12 mM imidaz-
ole, 20 mM β-mercaptoethanol, and lysozyme at 1 mg/mL,
followed by freezing in liquid nitrogen. Samples were then
thawed slowly on ice and centrifuged at 27,000 × g for 30 min at
4 °C. N-terminally His10-tagged Ub fusions of specific Ate1 iso-
forms, of untagged Liat1 and of 3haLiat1 in the soluble fraction
were purified by Ni-NTA chromatography, with elution of resin-
bound proteins by 0.3 M imidazole. The resulting samples were
dialyzed overnight at 4 °C against 5% (vol/vol) glycerol, 0.3 M
NaCl, 2 mM β-mercaptoethanol, and 50 mM Na2HPO4-NaH2PO4
(pH 8.0), containing EDTA-free protease inhibitor mixture
(Roche). The N-terminal His10-tagged Ub moiety was then
cleaved off by incubating dialyzed samples for 1 h at 37 °C with the
purified Usp2cc deubiquitylase (70) (added at 1:10 molar ratio).
The resulting samples were dialyzed against 5% (vol/vol) glycerol,
0.15 M NaCl, 10 mM β-mercaptoethanol, 50 mM Tris (pH 7.4),
followed by purification of (untagged) Ate1 and either Liat1
or 3haLiat1 using Mono-S chromatography (Pharmacia Biotech:
Id #9723125), with the elution gradient between 0.15 M and 1 M
NaCl in the above buffer. Peak fractions were pooled and dialyzed
overnight at 4 °C against 30% (vol/vol) glycerol 0.15 M NaCl,
10 mM β-mercaptoethanol, 50 mM Tris (pH 7.4).
Coimmunoprecipitation of Mouse Liat1 and Ate1 Isoforms. As in-
dicated in the legend to Fig. 2, mouse Ate1−/− EFs were trans-
fected with either pCB245, or pCB246, or pCB247, or pCB248
(expressing specific Ate1 isoforms) in the presence or absence of
pCB179, expressing mouse 3haLiat1 (Table S1). Transfections
were carried out using BioT reagent according to the manu-
facturer’s protocol. Forty-eight hours after transfection, cell ex-
tracts were prepared in lysis buffer [10% glycerol, 0.5% Triton
X-100, 0.15 M NaCl, 40 mM Hepes (pH7.6)] containing “com-
plete EDTA-free protease inhibitors” (Roche). Centrifugation-
clarified extracts were incubated with anti HA-EZ View beads
(Sigma E6799) for 3 h at 4 °C, with rotation. Beads were then
washed three times in lysis buffer. Immunoprecipitated proteins
were eluted in 2× SDS/PAGE sample buffer, followed by SDS/
12% PAGE, electroblotting of proteins onto PVDF membrane,
and the detection of 3haLiat1 and Ate1 using anti-ha and anti-
Ate1, respectively.
For “carrier-free” co-IP of purified recombinant 3haLiat1 and
Ate1 isoforms, 1 μg of purified Ate1 isoforms were incubated for
1 h at 4 °C in the presence or absence of 2 μg of purified Liat1
(∼fourfold molar excess) in 10% glycerol, 0.5% Triton-X100,
0.15 M NaCl, 40 mM Hepes (pH 7.6) containing “complete
EDTA-free protease inhibitors” (Roche). The mixture was then
incubated for one more 1 h in the presence of anti-Ate1 antibody
(0.4 μg) and for 3 more hours in the presence of 10 μL (set-
tled bead volume) of Protein A-agarose (Replicon; IAP300;
Lot#RN040321). The beads were then washed three times in the
above buffer. The proteins were eluted in 2× SDS/PAGE sample
buffer and heated at 95 °C for 5 min, followed by SDS/12%
PAGE and immunoblotting as described above.
Coimmunoprecipitation Assays with Liat1 and Putative Liat1 Ligands.
A cDNA encoding the N-terminally triply ha-tagged mouse Liat1
(3haLiat1) was constructed as briefly described in a section above.
The final ORF, encoding mouse 3haLiat1, was subcloned into
NheI/XhoI-cut pcDNA3.1 (Invitrogen), yielding pCB179 (Table
S1). Untagged mouse Ate1 cDNAs were amplified by PCR using
primers flanked by the BamHI and XhoI sites. The resulting
DNA fragments were subcloned into BamHI/XhoI-cut pcDNA-
Neo, yielding the plasmids pCB245 (Ate11B7A), pCB246
(Ate11B7B), pCB247 (Ate11A7A), and pCB248 (Ate11A7B) (Table
S1). DNA fragments (cDNAs) encoding mouse Jmjd6 and the
40S ribosomal protein S14 were amplified by PCR from a prep-
aration of total RNA (isolated from pooled mouse tissues).
DNA encoding a triple-flag epitope was added to the 3′ end of
these cDNAs using a multistep PCR protocol with primers
flanked with HindIII and ApaI, followed by subcloning into
HindIII/ApaI-cut pcDNA-Neo, a step that yielded pCB447
(expressing the 40S ribosomal protein S14) and pCB458
(expressing Jmjd6). Co-IP assays with 3haLiat1 vis-á-vis Jmjd63f
and S143f were carried similarly to Liat1-Ate1 co-IPs described
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above, except that mouse EFs were transfected with pCB179
(expressing 3haLiat1) and either pCB447 (S143f) or pCB458
(Jmjd63f), and proteins were immunoprecipitated from cell
extracts using magnetic anti-FLAG beads (Sigma), followed
by SDS/12% PAGE, and immunoblotting with anti-ha and
anti-flag.
GST Pulldowns. A cDNA encoding untagged mouse Liat1 cDNA
was amplified by PCR using primers flanked by EcoRI sites and
subcloned into EcoRI-cut pGEX-2t, yielding pCB404 (Table S1).
The GST-Liat1 ORF was amplified from pCB404 by PCR using
primers flanked by NheI and EcoRI sites, and the resulting DNA
fragment was subcloned into NheI/EcoRI digested pcDNA3.1
(Invitrogen), yielding pCB405 (Table S1). For expression of GST
alone in mammalian cells, cDNA encoding GST was amplified
from pGEX-2t using primers flanked by NheI and XhoI sites,
and the resulting DNA fragment was subcloned into NheI/XhoI-
cut pcDNA3.1, yielding pCB406. Wild-type mouse EFs were
transiently transfected with pCB405 and pCB406 using BioT
(Bioland Scientific) according to the manufacturers protocol.
Cells were lysed 48 h after transfection in 10% (vol/vol) glycerol,
0.5% Triton-X100, 0.15 M NaCl, 40 mM Hepes (pH 7.6) con-
taining “complete EDTA-free protease inhibitors” (Roche).
Clarified cell lysates were then incubated with Glutathione Su-
perflow Agarose (Qiagen) for 3 h at 4 °C, followed by affinity
chromatography in a glutathione-agarose minicolumn. Proteins
retained on the column were washed three times in lysis buffer,
and proteins were eluted in lithium-dodecyl sulfate-PAGE
sample buffer, followed by SDS/4–12% PAGE. Fractionated
proteins were silver-stained, and a separate set of the same
samples was fractionated identically but stained with Coomassie.
Specific Coomassie-stained bands were excised from the gel and
proteins in gel slices were analyzed (using tryptic digestion and
LC-MS/MS) at the Columbia University Protein Core Facility
(New York, NY).
1. Varshavsky A (2011) The N-end rule pathway and regulation by proteolysis. Protein Sci
20:1298–1345.
2. Hwang C-S, Shemorry A, Varshavsky A (2010) N-terminal acetylation of cellular pro-
teins creates specific degradation signals. Science 327(5968):973–977.
3. Eisele F, Wolf DH (2008) Degradation of misfolded protein in the cytoplasm is me-
diated by the ubiquitin ligase Ubr1. FEBS Lett 582(30):4143–4146.
4. Heck JW, Cheung SK, Hampton RY (2010) Cytoplasmic protein quality control deg-
radation mediated by parallel actions of the E3 ubiquitin ligases Ubr1 and San1. Proc
Natl Acad Sci USA 107(3):1106–1111.
5. Tasaki T, Sriram SM, Park KS, Kwon YT (2012) The N-end rule pathway. Annu Rev
Biochem 81:261–289.
6. Graciet E, Wellmer F (2010) The plant N-end rule pathway: Structure and functions.
Trends Plant Sci 15(8):447–453.
7. Dougan DA, Micevski D, Truscott KN (2012) The N-end rule pathway: From recognition
by N-recognins, to destruction by AAA+proteases. Biochim Biophys Acta 1823(1):83–91.
8. Mogk A, Schmidt R, Bukau B (2007) The N-end rule pathway for regulated proteolysis:
Prokaryotic and eukaryotic strategies. Trends Cell Biol 17(4):165–172.
9. Varshavsky A (1996) The N-end rule: Functions, mysteries, uses. Proc Natl Acad Sci USA
93(22):12142–12149.
10. Hwang C-S, Shemorry A, Auerbach D, Varshavsky A (2010) The N-end rule pathway is
mediated by a complex of the RING-type Ubr1 and HECT-type Ufd4 ubiquitin ligases.
Nat Cell Biol 12(12):1177–1185.
11. Hwang C-S, Shemorry A, Varshavsky A (2009) Two proteolytic pathways regulate DNA
repair by cotargeting the Mgt1 alkylguanine transferase. Proc Natl Acad Sci USA
106(7):2142–2147.
12. Hwang C-S, Varshavsky A (2008) Regulation of peptide import through phosphory-
lation of Ubr1, the ubiquitin ligase of the N-end rule pathway. Proc Natl Acad Sci USA
105(49):19188–19193.
13. Xia Z, et al. (2008) Substrate-binding sites of UBR1, the ubiquitin ligase of the N-end
rule pathway. J Biol Chem 283(35):24011–24028.
14. Hu R-G, Wang H, Xia Z, Varshavsky A (2008) The N-end rule pathway is a sensor of
heme. Proc Natl Acad Sci USA 105(1):76–81.
15. Hu R-G, et al. (2005) The N-end rule pathway as a nitric oxide sensor controlling the
levels of multiple regulators. Nature 437(7061):981–986.
16. Hwang C-S, et al. (2011) Ubiquitin ligases of the N-end rule pathway: Assessment of
mutations in UBR1 that cause the Johanson-Blizzard syndrome. PLoS ONE 6(9):e24925.
17. Wang H, Piatkov KI, Brower CS, Varshavsky A (2009) Glutamine-specific N-terminal
amidase, a component of the N-end rule pathway. Mol Cell 34(6):686–695.
18. Brower CS, Varshavsky A (2009) Ablation of arginylation in the mouse N-end rule
pathway: Loss of fat, higher metabolic rate, damaged spermatogenesis, and neuro-
logical perturbations. PLoS ONE 4(11):e7757.
19. Zenker M, et al. (2005) Deficiency of UBR1, a ubiquitin ligase of the N-end rule
pathway, causes pancreatic dysfunction, malformations and mental retardation
(Johanson-Blizzard syndrome). Nat Genet 37(12):1345–1350.
20. Prasad R, Kawaguchi S, Ng DTW (2010) A nucleus-based quality control mechanism
for cytosolic proteins. Mol Biol Cell 21(13):2117–2127.
21. Kurosaka S, et al. (2010) Arginylation-dependent neural crest cell migration is
essential for mouse development. PLoS Genet 6(3):e1000878.
22. Zhang F, Saha S, Shabalina SA, Kashina A (2010) Differential arginylation of actin isoforms
is regulated by coding sequence-dependent degradation. Science 329(5998):1534–1537.
23. Lee MJ, et al. (2005) RGS4 and RGS5 are in vivo substrates of the N-end rule pathway.
Proc Natl Acad Sci USA 102(42):15030–15035.
24. Piatkov KI, Brower CS, Varshavsky A (2012) The N-end rule pathway counteracts cell
death by destroying proapoptotic protein fragments. Proc Natl Acad Sci USA 109(27):
E1839–E1847.
25. Piatkov KI, Colnaghi L, Békés M, Varshavsky A, Huang TT (2012) The auto-generated
fragment of the Usp1 deubiquitylase is a physiological substrate of the N-end rule
pathway. Mol Cell 48(6):926–933.
26. Kwon YT, et al. (2002) An essential role of N-terminal arginylation in cardiovascular
development. Science 297(5578):96–99.
27. Lee MJ, et al. (2012) Characterization of arginylation branch of N-end rule pathway in
G-protein-mediated proliferation and signaling of cardiomyocytes. J Biol Chem
287(28):24043–24052.
28. Choi WS, et al. (2010) Structural basis for the recognition of N-end rule substrates by
the UBR box of ubiquitin ligases. Nat Struct Mol Biol 17(10):1175–1181.
29. Matta-Camacho E, Kozlov G, Li FF, Gehring K (2010) Structural basis of substrate
recognition and specificity in the N-end rule pathway. Nat Struct Mol Biol 17(10):
1182–1187.
30. Licausi F, et al. (2011) Oxygen sensing in plants is mediated by an N-end rule pathway
for protein destabilization. Nature 479(7373):419–422.
31. Sasidharan R, Mustroph A (2011) Plant oxygen sensing is mediated by the N-end rule
pathway: A milestone in plant anaerobiosis. Plant Cell 23(12):4173–4183.
32. Gibbs DJ, et al. (2011) Homeostatic response to hypoxia is regulated by the N-end rule
pathway in plants. Nature 479(7373):415–418.
33. Rao H, Uhlmann F, Nasmyth K, Varshavsky A (2001) Degradation of a cohesin subunit by
the N-end rule pathway is essential for chromosome stability.Nature 410(6831):955–959.
34. Kim ST, et al. (2013) The N-end rule proteolytic system in autophagy. Autophagy 9(7):
1100–1103.
35. Zhang G, Lin RK, Kwon YT, Li YP (2013) Signaling mechanism of tumor cell-induced
up-regulation of E3 ubiquitin ligase UBR2. FASEB J 27(7):2893–2901.
36. Tasaki T, et al. (2013) UBR box N-recognin-4 (UBR4), an N-recognin of the N-end rule
pathway, and its role in yolk sac vascular development and autophagy. Proc Natl Acad
Sci USA 110(10):3800–3805.
37. Fujiwara H, Tanaka N, Yamashita I, Kitamura K (2013) Essential role of Ubr11, but not
Ubr1, as an N-end rule ubiquitin ligase in Schizosaccharomyces pombe. Yeast 30(1):1–11.
38. Kitamura K, Fujiwara H (2013) The type-2 N-end rule peptide recognition activity of
Ubr11 ubiquitin ligase is required for the expression of peptide transporters. FEBS
Lett 587(2):214–219.
39. An JY, et al. (2010) UBR2 mediates transcriptional silencing during spermatogenesis
via histone ubiquitination. Proc Natl Acad Sci USA 107(5):1912–1917.
40. An JY, et al. (2012) UBR2 of the N-end rule pathway is required for chromosome
stability via histone ubiquitylation in spermatocytes and somatic cells. PLoS ONE 7(5):
e37414.
41. Sultana R, Theodoraki MA, Caplan AJ (2012) UBR1 promotes protein kinase quality
control and sensitizes cells to Hsp90 inhibition. Exp Cell Res 318(1):53–60.
42. Lee P, Sowa ME, Gygi SP, Harper JW (2011) Alternative ubiquitin activation/conju-
gation cascades interact with N-end rule ubiquitin ligases to control degradation of
RGS proteins. Mol Cell 43:392–405.
43. Román-Hernández G, Hou JY, Grant RA, Sauer RT, Baker TA (2011) The ClpS adaptor
mediates staged delivery of N-end rule substrates to the AAA+ ClpAP protease. Mol
Cell 43(2):217–228.
44. Yang F, et al. (2010) The ubiquitin ligase Ubr2, a recognition E3 component of the
N-end rule pathway, stabilizes Tex19.1 during spermatogenesis. PLoS ONE 5(11):e14017.
45. Ninnis RL, Spall SK, Talbo GH, Truscott KN, Dougan DA (2009) Modification of PATase
by L/F-transferase generates a ClpS-dependent N-end rule substrate in Escherichia
coli. EMBO J 28(12):1732–1744.
46. Schmidt R, Zahn R, Bukau B, Mogk A (2009) ClpS is the recognition component for
Escherichia coli substrates of the N-end rule degradation pathway. Mol Microbiol
72(2):506–517.
47. Holman TJ, et al. (2009) The N-end rule pathway promotes seed germination and
establishment through removal of ABA sensitivity in Arabidopsis. Proc Natl Acad Sci
USA 106(11):4549–4554.
48. Cai H, Hauser M, Naider F, Becker JM (2007) Differential regulation and substrate
preferences in two peptide transporters of Saccharomyces cerevisiae. Eukaryot Cell
6(10):1805–1813.
49. Schnupf P, Zhou J, Varshavsky A, Portnoy DA (2007) Listeriolysin O secreted by Listeria
monocytogenes into the host cell cytosol is degraded by the N-end rule pathway.
Infect Immun 75(11):5135–5147.
50. Hu R-G, et al. (2006) Arginyltransferase, its specificity, putative substrates, bidirectional
promoter, and splicing-derived isoforms. J Biol Chem 281(43):32559–32573.
Brower et al. www.pnas.org/cgi/content/short/1419587111 3 of 10
51. Graciet E, et al. (2006) Aminoacyl-transferases and the N-end rule pathway of pro-
karyotic/eukaryotic specificity in a human pathogen. Proc Natl Acad Sci USA 103(9):
3078–3083.
52. Kurosaka S, et al. (2012) Arginylation regulates myofibrils to maintain heart function
and prevent dilated cardiomyopathy. J Mol Cell Cardiol 53(3):333–341.
53. Wang J, et al. (2011) Arginyltransferase is an ATP-independent self-regulating en-
zyme that forms distinct functional complexes in vivo. Chem Biol 18(1):121–130.
54. Decca MB, et al. (2007) Post-translational arginylation of calreticulin: A new
isospecies of calreticulin component of stress granules. J Biol Chem 282(11):
8237–8245.
55. Tobias JW, Shrader TE, Rocap G, Varshavsky A (1991) The N-end rule in bacteria.
Science 254(5036):1374–1377.
56. Boso G, Tasaki T, Kwon YT, Somia NV (2013) The N-end rule and retroviral infection:
No effect on integrase. Virol J 10:233.
57. Saha S, Kashina A (2011) Posttranslational arginylation as a global biological regu-
lator. Dev Biol 358(1):1–8.
58. Belzil C, et al. (2013) A Ca2+-dependent mechanism of neuronal survival mediated
by the microtubule-associated protein p600. J Biol Chem 288(34):24452–24464.
59. Yamano K, Youle RJ (2013) PINK1 is degraded through the N-end rule pathway.
Autophagy 9(11):1758–1769.
60. Kim H-K, et al. (2014) The N-terminal methionine of cellular proteins as a degradation
signal. Cell 156(1-2):158–169.
61. Gibbs DJ, et al. (2014) Nitric oxide sensing in plants is mediated by proteolytic control
of group VII ERF transcription factors. Mol Cell 53(3):369–379.
62. Gibbs DJ, Bacardit J, Bachmair A, Holdsworth MJ (2014) The eukaryotic N-end rule
pathway: Conserved mechanisms and diverse functions. Trends Cell Biol 24(10):
603–611.
63. Licausi F, Pucciariello C, Perata P (2013) New role for an old rule: N-end rule-mediated
degradation of ethylene responsive factor proteins governs low oxygen response
in plants(F). J Integr Plant Biol 55(1):31–39.
64. Weits DA, et al. (2014) Plant cysteine oxidases control the oxygen-dependent branch
of the N-end-rule pathway. Nat Commun 5:3425.
65. Arnesen T, et al. (2009) Proteomics analyses reveal the evolutionary conservation and
divergence of N-terminal acetyltransferases from yeast and humans. Proc Natl Acad
Sci USA 106(20):8157–8162.
66. Starheim KK, Gevaert K, Arnesen T (2012) Protein N-terminal acetyltransferases:
When the start matters. Trends Biochem Sci 37(4):152–161.
67. Van Damme P, et al. (2012) N-terminal acetylome analyses and functional insights of
the N-terminal acetyltransferase NatB. Proc Natl Acad Sci USA 109(31):12449–12454.
68. Shemorry A, Hwang C-S, Varshavsky A (2013) Control of protein quality and stoi-
chiometries by N-terminal acetylation and the N-end rule pathway. Mol Cell 50(4):
540–551.
69. Brower CS, Veiga L, Jones RH, Varshavsky A (2010) Mouse Dfa is a repressor of TATA-
box promoters and interacts with the Abt1 activator of basal transcription. J Biol
Chem 285(22):17218–17234.
70. Catanzariti A-M, Soboleva TA, Jans DA, Board PG, Baker RT (2004) An efficient system
for high-level expression and easy purification of authentic recombinant proteins.
Protein Sci 13(5):1331–1339.
Fig. S1. Mouse Ate1 arginyltransferase (R-transferase), its gene organization, and its alternative exons. (A) Ate1 exons, including alternative exons (1A/1B and
7A/7B), with deduced lengths of the corresponding polypeptide segments indicated on top. (B) The deduced amino acid sequences of the alternative mouse
Ate1 exons 1A (29 residues) and 1B (36 residues), with identical residues in red and similar residues marked by asterisks. (C) Same as in B, but the 43-residue
alternative exons 7A and 7B.
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Fig. S2. Sequelogies (sequence similarities; see introductory paragraphs of the main text and ref. 1) among the Liat1 domains of different animals. This
particularly highly conserved ∼30-residue region of mouse Liat1, termed the Liat1 domain (it is highlighted in yellow in Figs. 3 and 4B), is aligned with Liat1
domains of other mammals, two nonmammalian vertebrates, and two invertebrates. At every position, a residue that is either identical or nonidentical to the
majority of residues at that position is either in red or in black, respectively. The numbers of last residues in each row are indicated on the right. Specific Liat1
proteins: mouse (Mus musculus) (NP_941039); rat (Rattus norvegicus) (NP_001103625.1); dog (Canis lupus) (XP_537762.4); rabbit (Oryctolagus cuniculus)
(XP_002719100); manatee (Trichechus manatus) (XP_004376319.1); cow (Bos taurus) (DAA19029); yak (Bos grunniens) (ELR61882); dolphin (Delphinus capensis)
(XP_004312659.1); whale (Balaenoptera musculus) (XP_004267289.1); rhinoceros (Diceros bicornis) (XP_004433508.1); macaque (Macaca mulatta)
(XP_001083490.1); baboon (Papio ursinus) (XP_003912083); bushbaby (Otolemur garnettii) (XP_003799182); gibbon (Hylobates lar lar) (XP_003280369);
orangutan (Pongo pygmaeus) (XP_002826835); gorilla (Gorilla beringei beringei) (XP_004058251.1); chimpanzee (Pan trogloditus) (XP_001174024); bonobo
(Pan paniscus) (XP_003816870); human (Homo sapiens) (NP_001013694.4); dove (Columba livia) (EMC80592); frog (Xenopus tropicalis) (XP_004911734); sea
anemone (Nematostella vectensis) (XP_001639507.1); acorn worm (Saccoglossus kowalewskii) (XP_002738466).
1. Varshavsky A (2004) ‘Spalog’ and ‘sequelog’: Neutral terms for spatial and sequence similarity. Curr Biol 14(5):R181–R183.
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Fig. S3. Sequence alignment of the full-length mouse and human Liat1 proteins. Note that significant sequelogies between mouse and human Liat1 are also
present outside the nearly identical Liat1 domains (yellow rectangle). The tandem repeats in human Liat1 (they are absent in the mouse and other nonprimate
Liat1 proteins) are highlighted by their arrangement in a column. At every position, a residue that is either identical or nonidentical to a majority-residue in this
alignment is either in red or in black, respectively. The colors of the negatively charged region (purple), of the positively charged region (green), and of the
Liat1 domain (yellow) (see also Fig. 4 and Fig. S2) are the same as in the corresponding regions of mouse Liat1 in Fig. 3A. The numbers of last residues in each
row are indicated on the right.
Fig. S4. Sequence alignment of the full-length mouse (vertebrate) and sea anemone (invertebrate) Liat1 proteins. Note the near-absence of sequelogies
outside the Liat1 domain (in yellow) and the positively charged region (in green). A 10-residue sequence of mouse Liat1 that becomes tandemly repeated in
Liat1 of primates (Fig. 4 and Fig. S3) is in blue. The numbers of last residues in each row are indicated on the right.
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Fig. S5. Purified Liat1 enhances the Ate1-mediated N-terminal arginylation in vitro. (A) Lane 1, purified mouse Ate11B7A R-transferase was incubated with
Asp-DHFRbt, a test protein, and with other components of a 14C-Arg-based Nt-arginylation system (see the main text and SI Experimental Procedures) followed
by SDS/PAGE and autoradiography. Lane 2, same as in lane 1 but with Arg-Asp-DHFRbt. Lane 3, same as in lane 1 but with Cys-DHFRbt. Lane 4, same as in lane 3
but in the presence of Ate1-lacking extract from Ate1−/− EF cells. Lanes 5–8, same as in lanes 1–4, respectively, but with purified mouse Ate11B7B R-transferase.
Lanes 9–12, same as in lanes 1–4, respectively, but with purified mouse Ate11A7A R-transferase. Lanes 13–16, same as in lanes 1–4, respectively, but with purified
mouse Ate11A7B R-transferase. Relative levels of Nt-arginylation of X-DHFRbt are plotted above the autoradiogram. (B) Lane 1, 14C-Arg-based Nt-arginylation
of lactalbumin (a model Nt-arginylation substrate bearing N-terminal Glu) (Fig. 1A). Lane 2, same as in lane 1 but in the absence of added Ate11B7A
R-transferase. (C) Lane 1, same as in A, lane 1 (an independent assay). Lane 2, same as in lane 1 but in the presence of a ∼fourfold molar excess (relative to Ate1)
of the purified mouse Liat protein. Lanes 3 and 4, same as in lanes 1 and 2, respectively, but with Cys-DHFRbt. Lanes 5–8, same as in lanes 1–4, respectively, but
with purified mouse Ate11B7B R-transferase. Lanes 9–12, same as in lanes 1–4, respectively, but with purified mouse Ate11A7A R-transferase. Lanes 13–16, same
as in lanes 1–4, respectively, but with purified mouse Ate11A7B R-transferase. Lane 17, same as in lane 2 but no added Ate1 (in the presence of Liat1). Lane 18,
same as in lane 17, but with Cys-DHFRbt.
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Fig. S6. Putative Liat1-binding proteins other than Ate1. (A) GST-Liat1 pulldown with an extract from mouse EF cells expressing N-terminally tagged GST-
Liat1, which was selectively retained, together with associated proteins, using glutathione-beads. Proteins were detected by silver staining after. Regions of
a Coomassie-stained counterpart of the silver-stained gel shown here (lane 2) containing proteins coisolated with GST-Liat1 were cut out (SI Experimental
Procedures) and analyzed using trypsin digestion and mass spectrometry (MS-MS). An indicated Liat1-binding large protein (>>250 kDa) could not be iden-
tified. (B) Coimmunoprecipitation of mouse 3haLiat1 (lane 1) with mouse Jmjd63f and the ribosomal protein S143f (main text). IB, immunoblotting (with anti-
flag and anti-ha); IP (in red), immunoprecipitation (with anti-flag). (C) Putative Liat1-binding proteins (besides the independently characterized Ate1, in red)
that have been identified through a separate Y2H screen using mouse Liat1 and mouse brain cDNA library. Five Liat1 ligands identified using GST-pulldowns
(A) are cited last (before Jmjd6).
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Table S1. Plasmids used in this study
Plasmid Description Source
pcDNA3.0-Neo AmpR; NeoR; Expression vector for cloning a gene of interest. Invitrogen
pcDNA3.1-Hyg AmpR; HygR; Expression vector for cloning a gene of interest. Invitrogen
pACT2 AmpR; LEU2 selectable marker in yeast. Y2H expression vector with PADH1 promoter.
Produces ha-tagged Gal4–AD fusion.
Clontech
pAS2 AmpR; (also called pAS1-CYH2); CYH selectable marker in yeast. Y2H expression vector
with PADH1 promoter. Produces ha-tagged Gal4–DBD fusion.
Clontech
pGEX-2t AmpR; Bacterial expression vector for expression of fusion proteins containing an
N-terminal GST moiety.
GE Healthcare Life Sciences
pH10UE AmpR; Bacterial expression vector for expression of fusion proteins containing an
N-terminal His10-ubiquitin moiety.
(70)
pA6 AmpR; pACT2-based plasmid encoding Gal4-AD fused to mouse 3haLiat1 under the
control of the yeast PADH1 promoter.
Present study
pCB132 AmpR; pAS2-based plasmid encoding Gal4 DBD fused to mouse haAte11B7A under the
control of the yeast PADH1 promoter.
Present study
pCB135 AmpR; pACT2-based plasmid encoding Gal4-AD fused to haAte11B7A under the control
of the yeast PADH1 promoter.
Present study
pCB141 AmpR; pACT2-based plasmid encoding Gal4-AD fused to Cdc42 under the control of the
yeast PADH1 promoter.
Present study
pCB142 AmpR; pAS2-based plasmid encoding Gal4 DBD fused to WASP under the control of the
yeast PADH1 promoter.
Present study
pCB164 AmpR; pAS2-based plasmid encoding Gal4 DBD fused to haATE11B7B under the control
of the yeast PADH1 promoter.
Present study
pCB165 AmpR; pACT2-based plasmid encoding Gal4-AD fused to haATE11B7B under the control
of the yeast PADH1 promoter.
Present study
pCB166 AmpR; pAS2-based plasmid encoding Gal4 DBD domain fused to haATE11A7A under the
control of the yeast PADH1 promoter.
Present study
pCB167 AmpR; pACT2-based plasmid encoding Gal4-AD fused to haATE11A7A under the control
of the yeast PADH1 promoter.
Present study
pCB179 AmpR; pcDNA3.1-based plasmid encoding mouse 3haLiat1 under the control of the
mammalian PCMV promoter
Present study
pCB239 AmpR; pAS2-based plasmid encoding Gal4 DBD domain fused to 3haLiat1 under the
control of the yeast PADH1 promoter.
Present study
pCB245 AmpR; pcDNA-Neo-based plasmid encoding mouse Ate11B7A (untagged) under the
control of the mammalian PCMV promoter.
Present study
pCB246 AmpR; pcDNA-Neo-based plasmid encoding mouse Ate11B7B (untagged) under the
control of the mammalian PCMV promoter.
Present study
pCB247 AmpR; pcDNA-Neo-based plasmid encoding mouse Ate11A7A (untagged) under the
control of the mammalian PCMV promoter.
Present study
pCB248 AmpR; pcDNANeo-based plasmid encoding mouse Ate11A7B (untagged) under the
control of the mammalian PCMV promoter.
Present study
pCB403 AmpR; pH10UE-based vector used for the bacterial expression of a fusion between
His10-ubiquitin and
3haLiat1.
Present study
pCB404 AmpR; Bacterial expression vector for expression of GST-Liat1. Present study
pCB405 AmpR; pcDNA3.1-based plasmid encoding GST-Liat1 under the control of the
mammalian PCMV promoter.
Present study
pCB406 AmpR; pcDNA3.1-based plasmid encoding GST under the control of the mammalian
PCMV promoter.
Present study
pCB407 AmpR; pH10UE-based vector used for the bacterial expression of a fusion between
His10-ubiquitin and Ate1
1B7A.
Present study
pCB408 AmpR; pH10UE-based vector used for the bacterial expression of a fusion between
His10-ubiquitin and Ate1
1B7B.
Present study
pCB409 AmpR; pH10UE-based vector used for the bacterial expression of a fusion between
His10-ubiquitin and Ate1
1A7A.
Present study
pCB410 AmpR; pH10UE-based vector used for the bacterial expression of a fusion between
His10-ubiquitin and Ate1
1A7B.
Present study
pCB432 AmpR; pACT2-based plasmid encoding Gal4-AD fused to haLiat1(1-228) under the control
of the yeast PADH1 promoter.
Present study
pCB433 AmpR; pACT2-based plasmid encoding Gal4-AD fused to haLiat1(61-228) under the
control of the yeast PADH1 promoter.
Present study
pCB434 AmpR; pACT2-based plasmid encoding Gal4-AD fused to haLiat1(113-228) under the
control of the yeast PADH1 promoter.
Present study
pCB435 AmpR; pACT2-based plasmid encoding Gal4-AD fused to haLiat1(135-228) under the
control of the yeast PADH1 promoter.
Present study
Brower et al. www.pnas.org/cgi/content/short/1419587111 9 of 10
Table S1. Cont.
Plasmid Description Source
pCB436 AmpR; pACT2-based plasmid encoding Gal4-AD fused to 3haLiat1(135-165) under the
control of the yeast PADH1 promoter.
Present study
pCB437 AmpR; pACT2-based plasmid encoding Gal4-AD fused to HAmLiat1(1-165) under the
control of the yeast PADH1 promoter.
Present study
pCB438 AmpR; pACT2-based plasmid encoding Gal4-AD fused to haLiat1(Δ135–165) under the
control of the yeast PADH1 promoter.
Present study
pCB439 AmpR; pACT2-based plasmid encoding Gal4-AD fused to haLiat1(95-228) under the
control of the yeast PADH1 promoter.
Present study
pCB447 AmpR; pcDNA-Neo-based plasmid encoding 40S ribosomal protein S143f under the
control of the mammalian PCMV promoter.
Present study
pCB458 AmpR; pcDNA-Neo-based plasmid encoding Jmjd63f under the control of the
mammalian PCMV promoter.
Present study
pCER006 AmpR; pH10UE-based vector used for the bacterial expression of a fusion between
His10-ubiquitin and mouse Liat1.
Present study
pCER019 AmpR; pACT2-based plasmid encoding Gal4-AD fused to haLiat1(Δ1–117) under the
control of the yeast PADH1 promoter.
Present study
pCER020 AmpR; pACT2-based plasmid encoding Gal4-AD fused to haLiat1(Δ1–124) under the
control of the yeast PADH1 promoter.
Present study
pCER021 AmpR; pACT2-based plasmid encoding Gal4-AD fused to haLiat1(113-165) under the
control of the yeast PADH1 promoter.
Present study
pCER022 AmpR; pACT2-based plasmid encoding Gal4-AD fused to haLiat1(Δ153–228) under the
control of the yeast PADH1 promoter.
Present study
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